Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
NetherlandsIPO:
17 March 1980Website:
http://www.philips.comNext earnings report:
29 January 2025Last dividends:
12 May 2022Next dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:04:46 GMTAnalysts recommendations
Institutional Ownership
PHG Latest News
PHG's third-quarter results reflect improved earnings but highlight challenges with declining sales in China and growth in other regions, showcasing mixed performance.
Philips' Q3 earnings showed flat sales but improved margins, driven by better productivity and pricing, despite weak performance in China. Risks include significant exposure to the Chinese market and competition, while opportunities lie in cost-cutting, AI implementation, and global growth. Due to China's economic weakness, Philips revised its sales growth guidance down to 0.5-1.5%, affecting stock performance and future expectations.
Philips (PHG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 300 points on Monday.
Philips faces challenges in China, but its overall fundamentals remain strong, with significant growth potential in other markets and segments like cardiovascular and ultrasound. Despite a 17% share price drop, Philips is undervalued at €24.20/share, presenting a compelling investment opportunity with an expected 11% annual EPS growth. The company shows margin improvements and resilience in various segments, indicating effective price hikes and operational adjustments amidst market uncertainties.
American depositary receipts (ADRs) of Koninklijke Philips (PHG) are tumbling more than 15% in premarket trading Monday after the Dutch conglomerate cut its 2024 sales outlook amid a "significant deterioration" in Chinese demand.
On Monday, Koninklijke Philips NV PHG reported third-quarter adjusted EPS of 0.32 euros (or $0.35), missing the consensus of 0.35 euros.
Shares of Philips slumped on Monday as the Dutch healthcare devices company lowered its sales outlook for the year.
Roy Jakobs, CEO of Philips, discusses the health care device maker's third-quarter results.
October 28, 2024 Third-quarter highlights Group sales amounted to EUR 4.4 billion, with flat comparable sales growth Income from operations was EUR 337 million Adjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of sales Operating cashflow of EUR 192 million, with a free cashflow of EUR 22 million Comparable order intake decreased by 2%, due to decline in China Outlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated range 0.5%-1.5%, Adjusted EBITA margin at around 11.5%, the upper end of current range; free cashflow at around EUR 0.9 billion, at lower end of current range Roy Jakobs, CEO of Royal Philips: “In the quarter, demand from hospitals and consumers in China further deteriorated, while we continue to see solid growth in other regions. We have adjusted our full-year sales outlook to reflect the continued impact from China.
What type of business is Koninklijke Philips NV?
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease. In addition, the company offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. Further, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. The company has strategic partnership agreements with TriHealth, Northwell, and Atrium Health. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
What sector is Koninklijke Philips NV in?
Koninklijke Philips NV is in the Healthcare sector
What industry is Koninklijke Philips NV in?
Koninklijke Philips NV is in the Medical Devices industry
What country is Koninklijke Philips NV from?
Koninklijke Philips NV is headquartered in Netherlands
When did Koninklijke Philips NV go public?
Koninklijke Philips NV initial public offering (IPO) was on 17 March 1980
What is Koninklijke Philips NV website?
https://www.philips.com
Is Koninklijke Philips NV in the S&P 500?
No, Koninklijke Philips NV is not included in the S&P 500 index
Is Koninklijke Philips NV in the NASDAQ 100?
No, Koninklijke Philips NV is not included in the NASDAQ 100 index
Is Koninklijke Philips NV in the Dow Jones?
No, Koninklijke Philips NV is not included in the Dow Jones index
When was Koninklijke Philips NV the previous earnings report?
No data
When does Koninklijke Philips NV earnings report?
The next expected earnings date for Koninklijke Philips NV is 29 January 2025